Protocol Single compound
BPC-157
Body Protection Compound-157
Pentadecapeptide derived from a gastric protein; studied in preclinical models of tendon, ligament, muscle and gut repair.
Compare side by side →Compared with:BPC-157 vs TB-500BPC-157 vs GHK-Cu
Protocol card · research reference
- Starting dose
- 0.25 mg
- Studied range
- 0.25–0.5 mg
- Frequency
- Once or twice daily
- Route
- Subcutaneous
- Cycle
- 4–8 weeks
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
BPC-157
Once or twice daily · units to draw on a U-100 syringe for a 0.25 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 | 5 u | 20 |
| 5 mg | 2 mL | 2.5 | 10 u | 20 |
| 5 mg | 3 mL | 1.67 | 15 u | 20 |
| 10 mg | 1 mL | 10 | 2.5 u | 40 |
| 10 mg | 2 mL | 5 | 5 u | 40 |
| 10 mg | 3 mL | 3.33 | 7.5 u | 40 |
Notes
- Most data is animal-model research.
- Commonly paired with TB-500 (see Wolverine Blend).
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical studies associate it with increased growth-hormone-receptor expression, angiogenesis pathways (including VEGF-related signalling) and lower inflammatory cytokines. The exact receptor target is not established.
02
Observed research endpoints
- A 2025 systematic review found 36 studies: 35 preclinical and 1 clinical.
- Animal models showed improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.
- The only clinical study was a small retrospective series: 7 of 12 patients with chronic knee pain reported relief for more than 6 months.
03
Regulatory & safety context
- Not FDA-approved for any use and listed as prohibited by the World Anti-Doping Agency.
- Reported half-life is under 30 minutes; it is metabolised in the liver and cleared by the kidneys.
- Preclinical safety studies reported no organ toxicity, but the 2025 review found no clinical safety data.
04
Citations
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485–495.2025-07Systematic reviewRead paper ↗
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972–1989.2018Narrative review (animal data)Read paper ↗
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon